homovanillic acid has been researched along with Depressive Disorder in 209 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
Depressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to investigate the discriminative power of a series of variables (including determination of depressive symptomatology by means of a visual analogue scale, determination of personality traits by means of the Karolinska Scales of Personality, determination of monoamine metabolites in CSF, platelet MAO activities, serum cortisol before and after dexamethasone suppression and urinary melatonin) in differentiating chronic pain patients from healthy subjects, and patients with idiopathic pain syndromes from patients with neurogenic pain syndromes." | 7.67 | Discrimination of idiopathic pain syndromes from neurogenic pain syndromes and healthy volunteers by means of clinical rating, personality traits, monoamine metabolites in CSF, serum cortisol, platelet MAO and urinary melatonin. ( Almay, BG; Häggendal, J; Johansson, F; Oreland, L; von Knorring, L; Wetterberg, L, 1986) |
| "Levels of cholecystokinin (CCK) peptides were measured in the CSF from 105 patients suffering from major depressive disorders admitted to a research psychiatric ward for diagnostic evaluation, by a radioimmunoassay method using two different antibodies." | 5.08 | Cholecystokinin in CSF from depressed patients: possible relations to severity of depression and suicidal behaviour. ( Agren, H; Harro, J; Löfberg, C; Oreland, L, 1998) |
| " The levels of the urinary main metabolites of norepinephrine 3-methoxy-4-hydroxyphenylglycol (MHPG), of dopamine homovanillic acid (HVA) and of serotonin 5-hydroxyindoleacetic acid (5-HIAA) were measured in 84 patients with major depressive disorder, 34 delusional and 50 nondelusional." | 3.69 | Biogenic amine metabolites in delusional (psychotic) depression and melancholia subtypes of major depression. ( Hatzimanolis, J; Lykouras, L; Malliaras, D; Markianos, M; Stefanis, C, 1994) |
| "In 8 cases of typical neuroleptic malignant syndrome (NMS), homovanillic acid (HVA), 5-hydroxyindole acetic acid (5-HIAA), noradrenaline (NA), and 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) levels in the cerebrospinal fluid (CSF) were assayed during both the active phase of NMS and after recovery." | 3.68 | Neuroleptic malignant syndrome: a study of CSF monoamine metabolism. ( Ishiguro, T; Nisijima, K, 1990) |
| "Lateral ventricle enlargement in schizophrenia has been positively correlated with poor premorbid competence, negative symptoms, and poor treatment response and negatively correlated with concentrations of homovanillic acid (HVA), a dopaminergic metabolite." | 3.68 | Lateral ventricle-brain ratio and balance between CSF HVA and 5-HIAA in schizophrenia. ( Caudle, J; Eccard, M; Jewart, RD; Lewine, RR; Pollard, W; Risby, E; Risch, SC; Stipetic, M, 1991) |
| "Performance on tasks tapping automatic and voluntary aspects of memory, attention, and motor speed was examined in 14 patients with major depressive disorder, before and after 3 weeks of treatment with clomipramine (150 mg/day), a potent serotonin and noradrenaline uptake blocker with anticholinergic side effects." | 3.68 | Memory effects of clomipramine treatment: relationship to CSF monoamine metabolites and drug concentrations in plasma. ( Asberg, M; Bartfai, A; Gustavsson, P; Mårtensson, B, 1991) |
| "A distinct pattern of neuropsychological deficits was associated with low homovanillic acid (HVA) in the cerebrospinal fluid of 21 patients with: Alzheimer's disease (9), Parkinson's disease (8) and major depressive disorders (4)." | 3.68 | Neuropsychological profile linked to low dopamine: in Alzheimer's disease, major depression, and Parkinson's disease. ( Albert, ML; Almozlino, A; Durso, R; Katz, DI; Smith, MC; Volicer, L; Wolfe, N, 1990) |
| "CSF levels of radioreceptorassayed endorphins Fraction I (EndFI, n = 92) and homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) (n = 118) were measured in patients with major depressive disorders according to Research Diagnostic Criteria (18% were psychotic; 11% hallucinated during the peak of the depressive episode)." | 3.67 | Hallucinations in patients with major depression. Interactions between CSF monoaminergic and endorphinergic indices. ( Agren, H; Terenius, L, 1985) |
| "The effects of electroconvulsive therapy (ECT) on sleep and cerebrospinal fluid (CSF) 5-hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) were studied in 11 male patients suffering from major depressive disorders severe enough to require ECT." | 3.67 | Effects of ECT on sleep and CSF biogenic amines in affective illness. ( Desmedt, D; Hoffmann, G; Kerkhofs, M; Linkowski, P; Mendlewicz, J, 1985) |
| "The aim of the present study was to investigate the discriminative power of a series of variables (including determination of depressive symptomatology by means of a visual analogue scale, determination of personality traits by means of the Karolinska Scales of Personality, determination of monoamine metabolites in CSF, platelet MAO activities, serum cortisol before and after dexamethasone suppression and urinary melatonin) in differentiating chronic pain patients from healthy subjects, and patients with idiopathic pain syndromes from patients with neurogenic pain syndromes." | 3.67 | Discrimination of idiopathic pain syndromes from neurogenic pain syndromes and healthy volunteers by means of clinical rating, personality traits, monoamine metabolites in CSF, serum cortisol, platelet MAO and urinary melatonin. ( Almay, BG; Häggendal, J; Johansson, F; Oreland, L; von Knorring, L; Wetterberg, L, 1986) |
| "Patients with idiopathic pain syndromes were compared with healthy volunteers and with patients suffering from chronic pain syndromes of neurogenic origin, with respect to the concentrations of the metabolites 5-hydroxy-indole-acetic acid (5-HIAA) and homovanillic acid (HVA) in cerebrospinal fluid (CSF)." | 3.67 | 5-HIAA and HVA in CSF in patients with idiopathic pain disorders. ( Almay, BG; Häggendal, J; Oreland, L; von Knorring, L, 1987) |
| " Recidivists who committed a new violent offense or arson had significantly lower cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid concentrations and blood glucose nadirs after oral glucose challenge than did nonrecidivists." | 3.67 | Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters. A follow-up study. ( Bartko, J; De Jong, J; Goodwin, FK; Linnoila, M; Virkkunen, M, 1989) |
| "Probenecid was administered to 7 unipolar depressed patients, 7 parkinsonians and 7 extrapyramidal patients with senile dementia matched for age and sex." | 3.66 | Biogenic amine disturbances in cerebrospinal fluid in parkinsonism and unipolar depression: use of the probenecid method. ( Mendlewicz, J; Noel, G; Vanderheyden, JE, 1981) |
| "In the cerebrospinal fluid of 38 patients with major depressive disorders the purine metabolites hypoxanthine and xanthine were positively correlated to the monoamine metabolites HVA and 5HIAA (p less than 0." | 3.66 | Purine and monoamine metabolites in cerebrospinal fluid: parallel purinergic and monoaminergic activation in depressive illness? ( Agren, H; Hällgren, R; Niklasson, F, 1983) |
| "5-Hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) were measured in the spinal fluid of 45 women hospitalized in a psychiatric department for major depression (14 cases), schizophrenia (18 cases) and alcohol dependence (13 cases)." | 3.66 | Relationship between cerebrospinal fluid amine metabolites, neuroendocrine findings and personality dimensions (Marke-Nyman scale factors) in psychiatric patients. ( Arató, M; Banki, CM, 1983) |
| "5-Hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) were measured in the lumbar cerebrospinal fluid of 57 drug-free female patients with DSM-III diagnoses of major unipolar or bipolar depression (n = 14), schizophrenic disorder (n = 18), alcohol dependence (n = 13) and a group of other disorders (n = 12)." | 3.66 | Amine metabolites and neuroendocrine responses related to depression and suicide. ( Arató, M; Banki, CM, 1983) |
| "Bupropion has been previously shown to be particularly beneficial in bipolar and atypical depression." | 2.69 | Bupropion slow-release response in depression: diagnosis and biochemistry. ( Bowden, CL; DeVane, CL; Dominguez, RA; Goodnick, PJ, 1998) |
| " Our results suggest that brofaromine at the clinically used dosage of 150 mg/day does indeed inhibit 5-HT uptake, as evidenced by measurements of 3H-paroxetine binding to platelets." | 2.67 | Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine. ( Feldtrauer, JJ; Germer, M; Graf, T; Howald, H; Waldmeier, PC, 1993) |
| "Patients with Alzheimer's disease (AD) have been reported to have a rate of nonsuppression on the dexamethasone suppression test (DST) comparable to that of patients with major depression." | 2.38 | The dexamethasone suppression test in Alzheimer's disease and major depression: relationship to dementia severity, depression, and CSF monoamines. ( Hill, JL; Lawlor, BA; Martinez, R; Mellow, AM; Molchan, SE; Sunderland, T, 1990) |
| "Furthermore, the response to sleep deprivation has important research implications." | 2.37 | Clinical and biological correlates of sleep deprivation in depression. ( Brown, P; Joffe, RT, 1984) |
| "With the exception of Parkinson's disease, there is little evidence that treatments which decrease DA function are potent inducers of depression, but it is argued that such a relationship might not necessarily be expected." | 2.36 | Dopamine and depression: a review of recent evidence. I. Empirical studies. ( Willner, P, 1983) |
| "None of the depressed COPD patients had suicidal ideation." | 1.39 | Positive association between the plasma levels of 5-hydroxyindoleacetic acid and the severity of depression in patients with chronic obstructive pulmonary disease. ( Edakuni, N; Hoshino, T; Imaoka, H; Ito, K; Kawayama, T; Matsunaga, K; Okamoto, M; Sekiduka-Kumano, T; Shoji, Y; Uchimura, N, 2013) |
| "To elucidate the influence of total sleep deprivation (TSD) on catecholaminergic neurotransmission, which is assumed to be disturbed in depression, 9 depressive patients collected consecutive 24-h urine samples prior to (baseline), during (TSD) and following total sleep deprivation (post-TSD)." | 1.29 | The influence of total sleep deprivation on urinary excretion of catecholamine metabolites in major depression. ( Berger, M; Müller, HU; Müller, WE; Riemann, D, 1993) |
| "Patients with chronic fatigue syndrome showed a significant reduction in basal plasma levels of MHPG and a significant increase in basal plasma levels of 5-HIAA." | 1.28 | Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syndrome: preliminary findings. ( Dale, JK; Demitrack, MA; Gold, PW; Kling, MA; Krahn, DD; Straus, SE, 1992) |
| "Bupropion responders were more likely to have trough blood levels above 30 ng/ml (chi 2 = 3." | 1.28 | Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. ( Brickman, A; Goodnick, PJ; Klimas, NG; Sandoval, R, 1992) |
| "Among 49 consecutive patients with Parkinson's disease, 40% were depressed according to DSM-III; they had major depression or dysthymic disorder accompanied by sleep disturbance, fatigue, psychomotor retardation, loss of self-esteem, and excessive guilt." | 1.27 | Clinical and biochemical features of depression in Parkinson's disease. ( Cote, L; Dyrenfurth, I; Frantz, A; Mayeux, R; Stern, Y; Williams, JB, 1986) |
| "Responders with bipolar depression had smaller reductions in MHPG levels than did responders with unipolar depression." | 1.27 | Effects of amitriptyline and imipramine on brain amine neurotransmitter metabolites in cerebrospinal fluid. ( Bowden, CL; Davis, JM; Hanin, I; Koslow, SH; Maas, JW; Robins, E, 1985) |
| "Most female patients with psychotic melancholia had elevated HVA levels." | 1.27 | Elevated plasma homovanillic acid in depressed females with melancholia and psychosis. ( Bowers, MB; Devanand, DP; Hoffman, FJ; Nelson, JC, 1985) |
| "Probenecid was administered to 7 unipolar depressed patients, 7 parkinsonians and 7 extrapyramidal patients with senile dementia matched for age and sex." | 1.26 | Serotonin and dopamine disturbances in patients with unipolar depression and Parkinsonism. ( Mendlewicz, J; Noel, G; Vanderheyden, JE, 1981) |
| "Desipramine plasma was much more effective than zimelidine plasma in inhibiting NA uptake in the same preparation." | 1.26 | A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. II. Biochemical findings. ( Aberg-Wistedt, A; Jostell, KG; Ross, SB; Sjöquist, B, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 122 (58.37) | 18.7374 |
| 1990's | 63 (30.14) | 18.2507 |
| 2000's | 20 (9.57) | 29.6817 |
| 2010's | 4 (1.91) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, X | 1 |
| Ogawa, S | 1 |
| Kunugi, H | 1 |
| Knorr, U | 1 |
| Forman, J | 1 |
| Pech, J | 1 |
| Kessing, LV | 1 |
| Sekiduka-Kumano, T | 1 |
| Kawayama, T | 1 |
| Ito, K | 1 |
| Shoji, Y | 1 |
| Matsunaga, K | 1 |
| Okamoto, M | 1 |
| Edakuni, N | 1 |
| Imaoka, H | 1 |
| Uchimura, N | 1 |
| Hoshino, T | 1 |
| Jokinen, J | 3 |
| Nordström, AL | 3 |
| Nordström, P | 4 |
| Heinz, A | 1 |
| Jones, DW | 1 |
| Bissette, G | 1 |
| Hommer, D | 1 |
| Ragan, P | 1 |
| Knable, M | 1 |
| Wellek, S | 1 |
| Linnoila, M | 22 |
| Weinberger, DR | 1 |
| Ehnvall, A | 1 |
| Sjögren, M | 1 |
| Zachrisson, OC | 1 |
| Agren, H | 15 |
| Sher, L | 2 |
| Oquendo, MA | 1 |
| Li, S | 1 |
| Huang, YY | 1 |
| Grunebaum, MF | 1 |
| Burke, AK | 1 |
| Malone, KM | 3 |
| Mann, JJ | 4 |
| Jähnel, M | 1 |
| Shinkai, K | 1 |
| Yoshimura, R | 2 |
| Ueda, N | 2 |
| Okamoto, K | 1 |
| Nakamura, J | 2 |
| Tajiri, S | 1 |
| Salomon, RM | 1 |
| Johnson, BW | 1 |
| Schmidt, DE | 1 |
| Arborelius, L | 1 |
| Eklund, MB | 1 |
| Kishida, I | 1 |
| Aklillu, E | 1 |
| Kawanishi, C | 1 |
| Bertilsson, L | 9 |
| Malkesman, O | 2 |
| Braw, Y | 1 |
| Ram, E | 1 |
| Maayan, R | 2 |
| Weizman, A | 2 |
| Kinor, N | 3 |
| Yadid, G | 3 |
| Weller, A | 3 |
| Shayit, M | 1 |
| Genud, R | 1 |
| Zangen, A | 1 |
| Lavi-Avnon, Y | 1 |
| Finberg, JP | 1 |
| Gispan-Herman, I | 1 |
| Stern, Y | 3 |
| Schroeder, M | 1 |
| Gelber, V | 1 |
| Bergman, SY | 1 |
| Overstreet, DH | 1 |
| Samuelsson, M | 1 |
| Okamoto, T | 1 |
| Ikenouchi-Sugita, A | 1 |
| Hori, H | 1 |
| Umene-Nakano, W | 1 |
| Inoue, Y | 1 |
| Bottiglieri, T | 2 |
| Lim, CK | 1 |
| Peters, TJ | 1 |
| Mayeux, R | 3 |
| Willner, P | 1 |
| Joffe, RT | 1 |
| Brown, P | 1 |
| Rosenthal, NE | 2 |
| Davenport, Y | 1 |
| Cowdry, RW | 3 |
| Webster, MH | 1 |
| Goodwin, FK | 5 |
| Loeb, DC | 1 |
| Roccatagliata, G | 1 |
| Albano, C | 1 |
| Abbruzzese, G | 1 |
| Banki, CM | 12 |
| Molnar, G | 4 |
| Fekete, I | 1 |
| Vanderheyden, JE | 2 |
| Noel, G | 2 |
| Mendlewicz, J | 5 |
| Träskman, L | 1 |
| Asberg, M | 8 |
| Sjöstrand, L | 1 |
| Vojnik, M | 3 |
| Davis, KL | 4 |
| Hollister, LE | 1 |
| Mathé, AA | 2 |
| Davis, BM | 1 |
| Rothpearl, AB | 2 |
| Faull, KF | 10 |
| Hsieh, JY | 1 |
| Barchas, JD | 4 |
| Berger, PA | 4 |
| Nordin, C | 3 |
| Siwers, B | 1 |
| Mohs, RC | 1 |
| Lantto, O | 1 |
| Scalia-Tomba, GP | 2 |
| Träskman-Bendz, L | 9 |
| Tybring, G | 1 |
| Taylor, MA | 1 |
| Abrams, R | 1 |
| Maas, JW | 11 |
| Kocsis, JH | 2 |
| Bowden, CL | 9 |
| Davis, JM | 10 |
| Redmond, DE | 2 |
| Hanin, I | 5 |
| Robins, E | 3 |
| Pinder, RM | 2 |
| Stulemeijer, SM | 2 |
| van Dorth, R | 2 |
| Montgomery, SA | 1 |
| Montgomery, DB | 1 |
| Aberg-Wistedt, A | 3 |
| Ross, SB | 2 |
| Jostell, KG | 2 |
| Sjöquist, B | 2 |
| Dahl, LE | 1 |
| Lundin, L | 1 |
| le Fèvre Honoré, P | 1 |
| Dencker, SJ | 1 |
| Oreland, L | 6 |
| Lapierre, YD | 1 |
| Wide, L | 1 |
| Niklasson, F | 2 |
| Hällgren, R | 1 |
| Korf, J | 1 |
| van den Burg, W | 1 |
| van den Hoofdakker, RH | 1 |
| Strolin Benedetti, M | 1 |
| Arató, M | 7 |
| Karoum, F | 3 |
| Miller, T | 1 |
| Potter, WZ | 8 |
| Osterberg, B | 1 |
| Franzén, O | 1 |
| Papp, Z | 3 |
| Kurcz, M | 1 |
| Kelwala, S | 1 |
| Jones, D | 1 |
| Sitaram, N | 1 |
| Koslow, SH | 8 |
| Javaid, J | 2 |
| Ebert, MH | 2 |
| van Kammen, DP | 1 |
| Post, RM | 3 |
| Litovitz, G | 1 |
| Scheinin, M | 4 |
| Chang, MD | 1 |
| Cutler, NR | 2 |
| Mårtensson, B | 5 |
| Thorén, P | 2 |
| Kraemer, GW | 1 |
| Lake, CR | 1 |
| McKinney, WT | 1 |
| Fink, M | 1 |
| Katz, MM | 4 |
| Gibbons, RL | 1 |
| Stokes, PE | 5 |
| Gerner, RH | 3 |
| Cohen, DJ | 2 |
| Fairbanks, L | 2 |
| Anderson, GM | 2 |
| Young, JG | 2 |
| Shaywitz, BA | 2 |
| Hare, TA | 2 |
| Kasa, K | 1 |
| Otsuki, S | 1 |
| Yamamoto, M | 1 |
| Sato, M | 1 |
| Kuroda, H | 1 |
| Ogawa, N | 1 |
| Hornykiewicz, O | 1 |
| Faustman, WO | 3 |
| Ringo, DL | 2 |
| Zarcone, VP | 2 |
| Benson, KL | 2 |
| Greene, KA | 1 |
| Csernansky, JG | 5 |
| Roy, A | 14 |
| Lundmark, J | 1 |
| Wålinder, J | 1 |
| Alling, C | 5 |
| Manniche, PM | 1 |
| Dalgaard, L | 1 |
| Swann, AC | 2 |
| Secunda, SK | 2 |
| Berman, N | 2 |
| Pollack, S | 1 |
| Markianos, M | 3 |
| Alevizos, B | 1 |
| Hatzimanolis, J | 2 |
| Stefanis, C | 3 |
| Frazer, A | 1 |
| Lykouras, L | 1 |
| Malliaras, D | 2 |
| Elliott, PJ | 1 |
| Rudorfer, MV | 6 |
| Skwerer, RG | 1 |
| Goodnick, PJ | 3 |
| Henry, J | 1 |
| Kumar, A | 1 |
| Salzman, C | 1 |
| Jimerson, D | 1 |
| Vasile, R | 1 |
| Watsky, E | 1 |
| Gerber, J | 1 |
| Müller, HU | 1 |
| Riemann, D | 1 |
| Berger, M | 1 |
| Müller, WE | 1 |
| Waldmeier, PC | 1 |
| Graf, T | 1 |
| Germer, M | 1 |
| Feldtrauer, JJ | 1 |
| Howald, H | 1 |
| Engström, G | 2 |
| Alsén, M | 2 |
| Regnéll, G | 3 |
| Radat, F | 1 |
| Morand, P | 1 |
| Nisijima, K | 2 |
| Oyafuso, K | 1 |
| Shimada, T | 1 |
| Hosino, H | 1 |
| Ishiguro, T | 2 |
| Northoff, G | 1 |
| Wenke, J | 1 |
| Demisch, L | 1 |
| Eckert, J | 1 |
| Gille, B | 1 |
| Pflug, B | 1 |
| Sweeney, JA | 1 |
| Brown, RP | 2 |
| Stanley, B | 2 |
| Stanley, M | 2 |
| Sheline, Y | 1 |
| Bardgett, ME | 1 |
| Bowers, MB | 7 |
| Arranz, B | 1 |
| Blennow, K | 1 |
| Eriksson, A | 1 |
| Månsson, JE | 1 |
| Marcusson, J | 1 |
| Gustavsson, P | 2 |
| Yoshida, K | 1 |
| Higuchi, H | 1 |
| Kamata, M | 1 |
| Yoshimoto, M | 1 |
| Shimizu, T | 1 |
| Hishikawa, Y | 1 |
| Löfberg, C | 1 |
| Harro, J | 1 |
| Dominguez, RA | 1 |
| DeVane, CL | 1 |
| Posener, JA | 1 |
| Schatzberg, AF | 1 |
| Williams, GH | 1 |
| Samson, JA | 1 |
| McHale, NL | 1 |
| Bessette, MP | 1 |
| Schildkraut, JJ | 1 |
| Little, JT | 1 |
| Ketter, TA | 1 |
| Frye, MA | 1 |
| Luckenbaugh, D | 1 |
| Berman, RM | 1 |
| Narasimhan, M | 1 |
| Miller, HL | 1 |
| Anand, A | 1 |
| Cappiello, A | 1 |
| Oren, DA | 1 |
| Heninger, GR | 2 |
| Charney, DS | 2 |
| Martin, P | 1 |
| Lambert, G | 1 |
| Johansson, M | 1 |
| Friberg, P | 1 |
| Bäckman, J | 1 |
| Delgado, PL | 1 |
| Moreno, FA | 1 |
| Onate, L | 1 |
| Gelenberg, AJ | 1 |
| Demitrack, MA | 1 |
| Gold, PW | 1 |
| Dale, JK | 1 |
| Krahn, DD | 1 |
| Kling, MA | 1 |
| Straus, SE | 1 |
| Hyland, K | 1 |
| Laundy, M | 1 |
| Godfrey, P | 1 |
| Carney, MW | 1 |
| Toone, BK | 1 |
| Reynolds, EH | 1 |
| Reddy, PL | 1 |
| Khanna, S | 1 |
| Subhash, MN | 1 |
| Channabasavanna, SM | 2 |
| Rao, BS | 1 |
| Vinge, E | 1 |
| Ohman, R | 1 |
| Swedin, A | 1 |
| Zachau, A | 1 |
| Yamadera, H | 1 |
| Kajimura, N | 1 |
| Kimura, M | 1 |
| Nakamura, S | 1 |
| Suzuki, H | 1 |
| Mori, T | 1 |
| Endo, S | 1 |
| Bryer, JB | 1 |
| Starkstein, SE | 1 |
| Votypka, V | 1 |
| Parikh, RM | 1 |
| Price, TR | 1 |
| Robinson, RG | 1 |
| Sandoval, R | 1 |
| Brickman, A | 1 |
| Klimas, NG | 1 |
| Sharma, RP | 1 |
| Javaid, JI | 2 |
| Pandey, GN | 1 |
| Janicak, PG | 1 |
| Maggioni, M | 1 |
| Picotti, GB | 1 |
| Bondiolotti, GP | 1 |
| Panerai, A | 1 |
| Cenacchi, T | 1 |
| Nobile, P | 1 |
| Brambilla, F | 1 |
| Jones, JS | 1 |
| Frances, AJ | 1 |
| Guido, JR | 1 |
| Winchel, R | 1 |
| Jibson, M | 1 |
| Przuntek, H | 1 |
| Kuhn, W | 1 |
| Wägner, A | 1 |
| Beck, O | 1 |
| Brodin, K | 1 |
| Montero, D | 1 |
| Lester, D | 1 |
| Molchan, SE | 3 |
| Hill, JL | 2 |
| Mellow, AM | 2 |
| Lawlor, BA | 3 |
| Martinez, R | 1 |
| Sunderland, T | 4 |
| Martinez, RA | 2 |
| Davis, CL | 1 |
| Rubinow, DR | 2 |
| Lewine, RR | 1 |
| Risch, SC | 1 |
| Risby, E | 1 |
| Stipetic, M | 1 |
| Jewart, RD | 1 |
| Eccard, M | 1 |
| Caudle, J | 1 |
| Pollard, W | 1 |
| Berrettini, WH | 1 |
| Vitiello, B | 1 |
| Tariot, PN | 1 |
| Cohen, RM | 1 |
| Dejong, J | 2 |
| Ferraro, T | 1 |
| Bartfai, A | 1 |
| Hassanyeh, F | 1 |
| Marshall, EF | 1 |
| Mazure, CM | 3 |
| Nelson, JC | 4 |
| Jatlow, PI | 2 |
| King, RJ | 2 |
| Moses, JA | 1 |
| Lamparski, D | 2 |
| George, T | 1 |
| Goekoop, JG | 1 |
| Knoppert-van der Klein, EA | 1 |
| Wolfe, N | 1 |
| Katz, DI | 1 |
| Albert, ML | 1 |
| Almozlino, A | 1 |
| Durso, R | 1 |
| Smith, MC | 1 |
| Volicer, L | 1 |
| Baker, NJ | 1 |
| Staunton, M | 1 |
| Adler, LE | 1 |
| Gerhardt, GA | 1 |
| Drebing, C | 1 |
| Waldo, M | 1 |
| Nagamoto, H | 1 |
| Freedman, R | 1 |
| Terenius, L | 1 |
| Mühlbauer, HD | 1 |
| Wistedt, B | 1 |
| Joyce, PR | 1 |
| Pickar, D | 6 |
| Doran, AR | 4 |
| Ninan, P | 1 |
| Paul, SM | 4 |
| Golden, RN | 3 |
| Calil, HM | 1 |
| Ross, RJ | 1 |
| Hoffmann, G | 1 |
| Linkowski, P | 1 |
| Kerkhofs, M | 1 |
| Desmedt, D | 1 |
| Vandel, S | 1 |
| Vandel, B | 1 |
| Bonin, B | 1 |
| Camejo, Z | 1 |
| Sandoz, M | 1 |
| Allers, G | 1 |
| Volmat, R | 1 |
| Williams, JB | 2 |
| Cote, L | 2 |
| Frantz, A | 1 |
| Dyrenfurth, I | 1 |
| Brown, GL | 2 |
| Swann, A | 1 |
| Casper, R | 2 |
| Gibbons, RD | 2 |
| Mefford, IN | 1 |
| von Knorring, L | 2 |
| Almay, BG | 2 |
| Häggendal, J | 2 |
| Johansson, F | 1 |
| Wetterberg, L | 1 |
| Sano, M | 1 |
| Koyama, T | 1 |
| Lowy, MT | 1 |
| Meltzer, HY | 1 |
| Kilts, CD | 2 |
| Cross, CK | 1 |
| Koslow, S | 1 |
| Everett, D | 1 |
| Dent, RR | 1 |
| Ghadirian, AM | 1 |
| Kusalic, M | 1 |
| Young, SN | 1 |
| Peabody, CA | 2 |
| Whiteford, HA | 2 |
| Casper, RC | 1 |
| Stoll, PM | 1 |
| Gjerris, A | 1 |
| Werdelin, L | 1 |
| Gjerris, F | 1 |
| Sørensen, PS | 1 |
| Rafaelsen, OJ | 1 |
| Price, LH | 1 |
| Warner, MD | 1 |
| Risby, ED | 1 |
| Hsiao, JK | 2 |
| Bartko, JJ | 1 |
| Timmerman, L | 1 |
| de Beurs, P | 1 |
| Tan, BK | 1 |
| Leijnse-Ybema, H | 1 |
| Sanchez, C | 1 |
| Høpfner Petersen, HE | 1 |
| Cohen Stuart, MH | 1 |
| France, RD | 1 |
| Urban, BJ | 1 |
| Pelton, S | 1 |
| Hong, JS | 1 |
| Nemeroff, CB | 1 |
| Lykouras, E | 1 |
| Adinoff, B | 2 |
| Roehrich, L | 1 |
| Custer, R | 1 |
| Lorenz, V | 1 |
| Barbaccia, M | 1 |
| Guidotti, A | 1 |
| Costa, E | 1 |
| Chang, SS | 1 |
| Pfefferbaum, A | 1 |
| Tandon, R | 1 |
| Greden, JF | 1 |
| Kilkowski, J | 1 |
| Anderson, PJ | 1 |
| Kraemer, H | 1 |
| Virkkunen, M | 1 |
| De Jong, J | 2 |
| Bartko, J | 1 |
| Nyberg, S | 1 |
| Toresson, G | 1 |
| Brodin, E | 1 |
| Fritze, J | 1 |
| Laux, G | 1 |
| Sofic, E | 2 |
| Koronakis, P | 1 |
| Schoerlin, MP | 1 |
| Riederer, P | 2 |
| Beckmann, H | 1 |
| Breier, A | 3 |
| Balla, KZ | 1 |
| Devanand, DP | 2 |
| Hoffman, FJ | 3 |
| Sackeim, HA | 1 |
| Wolkowitz, OM | 2 |
| Doran, A | 1 |
| Siever, LJ | 1 |
| Kruzik, P | 1 |
| Gabriel, E | 1 |
| Anokhina, ID | 1 |
| Bol'shakova, TD | 1 |
| Bremer, GP | 1 |
| Buniatian, AF | 1 |
| Ignatenko, LL | 1 |
| Sherer, MA | 2 |
| Sack, DA | 1 |
| James, SP | 1 |
| Wehr, TA | 1 |
| Oliver, J | 1 |
| Swigar, ME | 1 |
| Goicoechea, N | 1 |
| Harvey, NS | 1 |
| Jimerson, DC | 1 |
| Sutton, ME | 1 |
| Hoffman, F | 1 |
| Miller, KB | 1 |
| Douillet, P | 1 |
| Wilkins, JN | 1 |
| Uhde, TW | 1 |
| Ballenger, JC | 1 |
| Syvälahti, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder.[NCT03418675] | Phase 2 | 80 participants (Actual) | Interventional | 2018-11-26 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Neural Correlates of Depressive Symptoms and Reward Related Mechanisms Following AMPT Depletion in Remitted Depressed Patients Off Treatment and Healthy Controls[NCT00082030] | 71 participants (Actual) | Observational | 2004-04-19 | Completed | |||
| Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715] | Phase 4 | 23 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923] | Phase 4 | 95 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Repetitive Transcranial Magnetic Stimulation (rTMS) for Motor and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial[NCT01080794] | 61 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| Combining a Dopamine Agonist and Selective Serotonin Reuptake Inhibitor for Treatment of Depression: A Double-Blind, Randomized Study[NCT00086307] | Phase 2 | 39 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A clinician-administered assessment of anxiety that will be assessed at all study visits (Visit 1-Visit 8). Changes in scores from baseline to final visit will be assessed. Higher scores (up to 56) indicate higher levels of anxiety, with 0 being no symptoms of anxiety. (NCT03418675)
Timeframe: assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to Week 12) is reported
| Intervention | change in score on a scale (Mean) |
|---|---|
| Placebo | -2.41 |
| Rexulti | -4.88 |
A clinician-administered assessment of depression that will be assessed at all study visits (Visits 1-8). Higher total scores indicate higher levels of depression (up to 52), while a score of 0 would indicate no depressive symptoms. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported
| Intervention | change in score on a scale (Mean) |
|---|---|
| Placebo | -2.09 |
| Rexulti | -3.81 |
A self-report assessment of impulsivity that will be assessed at baseline and visit 8. The BIS is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Items are scored on a 4-point scale: (Rarely/Never = 1, Occasionally = 2, Often = 3, Almost Always/Always = 4). These scores are summed to produce an overall impulsivity score ranging from 30 (not impulsive) to 120 (extremely impulsive). (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 76.53 | 68.13 |
| Rexulti | 72.27 | 70.5 |
A self rated scale used to measure severity and change. The first 12 items of the scale are on a scale from 1-5, with 5 meaning that the item caused extreme distress, severe difficulties in relationships, and/or kept them from getting things done. The lowest rating (1) means it caused little or no problems. Items 13-15 (positive behaviors) are rated according to frequency. Completed at every visit. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 40.90 | 29.15 |
| Rexulti | 40.54 | 23.15 |
"A self-report scale measuring suicidality. Subjects will complete the scale at all visits. Subjects are asked about suicidal thoughts. If answers are no, rater can proceed to suicidal behavior section where subject is asked about any non-suicidal self injurious behavior. If yes, subject is asked about intensity of ideations. In the event of serious threat to themselves, the subject will be escorted to the emergency room. Total score indicates severity of suicidal ideation and behavior, with lower scores representing lower levels of suicidality and higher scores representing higher levels of suicidality. A score of 0 would reflect no suicidality present, whereas a maximum score of 5 would reflect active suicidal ideation with intent to act." (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 1.15 | 0.23 |
| Rexulti | 0.73 | 0.08 |
A short-structured interview that assesses comorbid psychiatric disorders according to the DSM 5 criteria. This assessment will be done during the baseline visit. (NCT03418675)
Timeframe: Baseline (Week 1)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Major Depressive Episode (Current) | Major Depressive Episode (Past) | Manic Episode (Current) | Manic Episode (Past) | Hypomanic Episode (Current) | Bipolar I Disorder (Current) | Bipolar I Disorder (Past) | Bipolar II Disorder (Current) | Bipolar II Disorder (Past) | Panic Disorder (Current) | Panic Disorder (Lifetime) | Agoraphobia (Current) | Social Anxiety Disorder (Current) | Obsessive Compulsive Disorder (Current) | Post Traumatic Stress Disorder (Current) | Alcohol Use Disorder (Past 12 months) | Substance Use Disorder (Past 12 months) | Any Psychotic Disorder (Current) | Any Psychotic Disorder (Lifetime) | Major Depressive Disorder with Psychotic Features (Current) | Major Depressive Disorder with Psychotic Features (Past) | Anorexia Nervosa (current) | Bulimia Nervosa (Current) | Binge Eating Disorder (Current) | Generalized Anxiety Disorder (Current) | Antisocial Personality Disorder (Lifetime) | ADHD Combined Type (Current) | ADHD Inattentive Type (Current) | ADHD Hyperactive Type (Current) | Tourette's Syndrome (Lifetime) | Persistent Motor Tic Disorder (Lifetime) | Provisional Vocal Tic Disorder (Lifetime) | Provisional Tic Disorder (Lifetime) | Specific Phobia | Body Dysmorphic Disorder (Current) | |
| Placebo | 16 | 12 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 6 | 11 | 7 | 6 | 3 | 9 | 13 | 11 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 10 | 8 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 4 | 3 |
| Rexulti | 18 | 18 | 2 | 3 | 0 | 0 | 0 | 0 | 1 | 6 | 10 | 9 | 9 | 3 | 12 | 8 | 8 | 0 | 1 | 0 | 0 | 1 | 4 | 4 | 15 | 4 | 4 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 2 |
A self-report assessment of patient perceived quality of life that will be assessed at baseline and visit 8. Higher scores indicate a higher quality of life, whereas lower scores indicate a lower quality of life. Participants are asked to rate the importance of each domain on a 3-point scale ranging from 1=not important to 3=very important, and to rate how satisfied they are with that domain on a 6-point scale, ranging from -3=very dissatisfied to +3=very satisfied. In scoring, importance ratings are multiplied by satisfaction ratings to produce weighted satisfaction scores for each of the 16 domains. Weighted satisfaction scores are summed and divided by the number of domains that were rated as important or very important to produce a raw score, which is then converted to a t-score, which provides a proxy measurement for perceived quality of life. T-scores range from very low perceived quality of life (0-36) to high perceived quality of life (58-77). (NCT03418675)
Timeframe: Baseline (Week 1), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 28.89 | 30.75 |
| Rexulti | 28.70 | 35.71 |
A self-report scale assessing Borderline Personality severity that will be assessed at all visits.This scale is assessing severity and change in BPD symptoms. This is a 9-item scale measuring severity of different aspects of Borderline Personality Disorder, with each item rated on a 0-4 scale, 0=no symptoms, 4=severe symptoms. Total scores range from 0-36. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
| Placebo | 18.2 | 12.8 | 10.7 | 10.7 | 9.7 | 9.6 | 8.7 | 9.3 |
| Rexulti | 17.6 | 10.9 | 7.9 | 8.0 | 7.0 | 6.6 | 6.0 | 5.8 |
Subjects will complete the SDS at all visits. The change in scores from baseline to study completion will be assessed. The scale itself assesses the level of disability from borderline personality disorder (or target disorder) with higher scores indicating a more debilitating disorder. Scores range from 0-30. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
| Placebo | 17.3 | 13.3 | 11.5 | 12.4 | 11.7 | 11.2 | 12.0 | 12.7 |
| Rexulti | 15.8 | 10.7 | 7.8 | 7.8 | 7.0 | 7.9 | 6.9 | 7.7 |
An instrument that helps evaluate a broad range of psychological problems and symptoms of Borderline Personality Disorder psychopathology. This will be assessed at baseline and visit 8.The 115 items are rated by using a 5-step Likert scale (0=not at all, 4=very strong) and provide a global picture of borderline psychopathology. Global scores of borderline psychopathology are calculated by summing 12 items and range from 0-48. Higher scores indicate more severe symptoms of Borderline Personality Disorder. (NCT03418675)
Timeframe: Baseline, Visit 8 (Week 12)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 26.17 | 20.25 |
| Rexulti | 25.42 | 14.21 |
A clinician-administered scale assessing Borderline Personality Scale severity at all study visits. Scores range from 0-36. Higher scores represent worse Borderline Personality Disorder severity, and lower scores represent milder Borderline Personality Disorder severity. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
| Placebo | 14.9 | 7.6 | 4.7 | 6 | 4.2 | 5.7 | 5 | 8.4 |
| Rexulti | 14.9 | 6.7 | 5.3 | 4.4 | 4.5 | 4.9 | 4 | 3.1 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| QUET | 65.5 |
Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Drinking Days per Week (Mean) |
|---|---|
| QUET | 2.7 |
Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 2.84 |
| Oral Risperidone Aka Risperdal | 3.46 |
A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of impairment (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 50.8 |
| Oral Risperidone Aka Risperdal | 49.9 |
A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of symptoms (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 78.2 |
| Oral Risperidone Aka Risperdal | 75.5 |
A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal unit of severity (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 4.02 |
| Oral Risperidone Aka Risperal | 3.96 |
Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | heavy drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | -.11 |
| Oral Risperidone Aka Risperal | .68 |
Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 43 |
| Oral Risperidone Aka Risperdal | 28 |
To establish the safety and tolerability of rTMS in Parkinson's Disease. (NCT01080794)
Timeframe: Baseline through Month 6
| Intervention | incidents of an adverse event (Number) |
|---|---|
| Double rTMS | 18 |
| M1 Active rTMS + DLPFC Sham rTMS | 14 |
| DLPFC Active rTMS + M1 Sham rTMS | 1 |
| Double Sham rTMS | 1 |
To evaluate apathy in Parkinson's Disease. The AES mean scores were reported for each group at each time point. The AES Score Range is 0-42, where higher the score indicates greater severity of the apathy symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 18.7 | 18.1 | 19.0 | 19.3 | 15.8 |
| Double rTMS | 15.6 | 16.2 | 17 | 16.9 | 17.8 |
| Double Sham rTMS | 16.3 | 15.5 | 15.0 | 16.1 | 16.2 |
| M1 Active rTMS + DLPFC Sham rTMS | 15.9 | 16.9 | 14.6 | 15.1 | 12.4 |
To assess mood symptoms in Parkinson's Disease. The BDI-II mean scores were reported for each group at each time point. The BDI-II Score Range is 0 - 63, where higher the score indicates greater severity of the mood symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 21.7 | 18.2 | 20.2 | 19.0 | 15.7 |
| Double rTMS | 23.2 | 20.7 | 16.4 | 17.9 | 20.1 |
| Double Sham rTMS | 18.8 | 13.7 | 13.1 | 14.7 | 16.8 |
| M1 Active rTMS + DLPFC Sham rTMS | 18.5 | 16.5 | 16.7 | 19.1 | 16.3 |
To evaluate anxiety in Parkinson's Disease. The CAS mean scores were reported for each group at each time point. The CAS Score Range is 0 - 100, where higher the score indicates greater severity of the anxiety symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 33.4 | 27.6 | 30.8 | 31.4 | 24.8 |
| Double rTMS | 36.3 | 34.2 | 31.7 | 33.1 | 33.4 |
| Double Sham rTMS | 37.5 | 32.4 | 28.2 | 28.5 | 35.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 34.3 | 31.0 | 30.8 | 27.3 | 28.1 |
To assess symptom severity and treatment response in Parkinson's Disease. The CGI mean scores were reported for each group at each time point. The CGI Score Range is 1 - 8, where higher the score indicates greater severity of illness or worsening of illness. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (Pre-Treatment): Severity | Week 1 Post Treatment: Severity | Week 1 Post Treatment: Improvement | Month 1 Post Treatment: Severity | Month 1 Post Treatment: Improvement | Month 3 Post Treatment: Severity | Month 3 Post Treatment: Improvement | Month 6 Post Treatment: Severity | Month 6 Post Treatment: Improvement | |
| DLPFC Active rTMS + M1 Sham rTMS | 4.3 | 4.7 | 3.5 | 4.4 | 3.7 | 4.4 | 3.6 | 4.3 | 3.7 |
| Double rTMS | 4.9 | 4.8 | 3.6 | 4.4 | 3.5 | 4.6 | 3.7 | 4.2 | 3.5 |
| Double Sham rTMS | 3.6 | 3.9 | 3.0 | 4.1 | 3.5 | 4.4 | 3.6 | 4.6 | 3.4 |
| M1 Active rTMS + DLPFC Sham rTMS | 4.7 | 4.9 | 3.5 | 4.8 | 3.8 | 3.8 | 3.4 | 5.0 | 4.2 |
"To evaluate the depressive mood symptoms in PD.~The HAM-D mean scores were reported for each group at each time point. The HAM-D Score Range is 0 - 56, where higher the score indicates greater severity of depressive mood symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post-Treatment | Month 1 Post-Treatment | Month 3 Post-Treatment | Month 6 Post-Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 13.8 | 9.4 | 12.4 | 10.4 | 10.4 |
| Double rTMS | 15.2 | 11.3 | 10.6 | 10.7 | 10.4 |
| Double Sham rTMS | 14.1 | 9.3 | 8.0 | 11.1 | 10.4 |
| M1 Active rTMS + DLPFC Sham rTMS | 16.7 | 11.2 | 10.1 | 10.1 | 8.6 |
To screen and follow cognitive function in Parkinson's Disease. The MoCA mean scores were reported for each group at each time point. The MoCA Score Range is 0 - 30, where 26-30 indicates normal cognition. (NCT01080794)
Timeframe: pre-treatment; 0,1,3, and 6 months post-treatment
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 27.3 | 26.3 | 26.8 | 26.7 | 26.6 |
| Double rTMS | 28.2 | 26.8 | 28.8 | 26.5 | 28.0 |
| Double Sham rTMS | 26.2 | 27.8 | 28.7 | 24.9 | 28.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 26.6 | 27.1 | 27.2 | 25.3 | 27.9 |
"To evaluate the motor symptoms in Parkinson's Disease.~The UPDRS-III mean scores were reported for each group at each time point. The UPDRS-III Score Range is 0 - 56, where higher the score indicates greater severity of the motor symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post-Treatment | Month 1 Post-Treatment | Month 3 Post-Treatment | Month 6 Post-Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 32.8 | 30.3 | 29.3 | 31.5 | 28.8 |
| Double rTMS | 32.3 | 31.2 | 30.1 | 29.6 | 30.5 |
| Double Sham rTMS | 28.9 | 28.2 | 28.6 | 28.6 | 29.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 33.1 | 27.4 | 28.1 | 33.2 | 30.6 |
To assess the quality of life (QOL) in Parkinson's Disease. The PDQ-39 mean scores were reported for each group at each time point. The PDQ-39 Score Range is 0 - 156, where higher the score indicates greater impact on quality of life. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 51.9 | 46.8 | 49.4 | 49.4 | 49 |
| Double rTMS | 57.6 | 51.2 | 49.9 | 51.7 | 50.5 |
| Double Sham rTMS | 55.5 | 43.1 | 40.9 | 43.1 | 47.5 |
| M1 Active rTMS + DLPFC Sham rTMS | 61.5 | 60.7 | 56.8 | 53.1 | 48.3 |
"To assess apathy, cognition, depression, activities of daily living (ADL), quality of life (QOL), and motor symptoms in Parkinson's Disease.~The UPDRS I, II, IV total mean scores were reported for each group at each time point. The UPDRS I, II, IV scores were added together for each patient, with a total score range of 0 - 91, where higher the score indicates greater severity of the symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 21.5 | 19.3 | 19.9 | 18.9 | 20.2 |
| Double rTMS | 25.4 | 23.3 | 21.8 | 21.1 | 23.8 |
| Double Sham rTMS | 19.6 | 15.5 | 16.5 | 16.9 | 18.8 |
| M1 Active rTMS + DLPFC Sham rTMS | 26.1 | 23.2 | 23.0 | 23.2 | 22.7 |
The Montgomery Asberg Depression Rating Scale (MADRS) is a 10 item scale for assessing the severity of depression. Items are rated on a scale of 0 to 6, so the maximum score is 60 and the minimum is 0, where 60 is the most severe depression. Scores of 18 or greater are generally considered to indicate a moderate level of depression. (NCT00086307)
Timeframe: Weekly
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Pramipexole | 22.629 |
| Escitalopram | 26.102 |
| Escitalopram and Pramipexole | 29.455 |
19 reviews available for homovanillic acid and Depressive Disorder
| Article | Year |
|---|---|
[Vanillylmandelic acid (VMA) and homovanillic acid (HVA)].
Topics: Adrenal Gland Neoplasms; Biomarkers; Chromatography, High Pressure Liquid; Chronic Disease; Depressi | 2005 |
Behavioral manifestations of movement disorders. Parkinson's and Huntington's disease.
Topics: Adult; Aged; Dementia; Depression; Depressive Disorder; Homovanillic Acid; Humans; Huntington Diseas | 1984 |
Dopamine and depression: a review of recent evidence. I. Empirical studies.
Topics: Amphetamine; Antipsychotic Agents; Brain; Bromocriptine; Depressive Disorder; Dihydroxyphenylalanine | 1983 |
Clinical and biological correlates of sleep deprivation in depression.
Topics: Bipolar Disorder; Circadian Rhythm; Depressive Disorder; Homovanillic Acid; Humans; Hydrocortisone; | 1984 |
Reassessing the bipolar-unipolar dichotomy.
Topics: Bipolar Disorder; Catechol O-Methyltransferase; Depressive Disorder; Diagnosis, Differential; Female | 1980 |
[Biochemistry of depression and antidepressants].
Topics: Antidepressive Agents; Brain Chemistry; Catechol O-Methyltransferase; Depressive Disorder; Dopamine; | 1982 |
Cerebrospinal fluid probenecid studies: a reinterpretation.
Topics: Biological Transport; Brain; Depressive Disorder; Dopamine; Homovanillic Acid; Humans; Hydroxyindole | 1983 |
CSF monoamine metabolites, depression, and suicide.
Topics: Aggression; Analysis of Variance; Biogenic Amines; Depressive Disorder; Dexamethasone; Homicide; Hom | 1984 |
Recent biologic studies on suicide.
Topics: 3,4-Dihydroxyphenylacetic Acid; Brain; Depressive Disorder; Dopamine; Follow-Up Studies; Homovanilli | 1994 |
Genetic and biologic risk factors for suicide in depressive disorders.
Topics: Adoption; Denmark; Depressive Disorder; Diseases in Twins; Dopamine; Family; Female; Follow-Up Studi | 1993 |
[Prediction of therapeutic response in depressive states].
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1996 |
[Specifics of a dual action: toward new and more effective antidepressants?].
Topics: Acetylcholine; Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Brain; Cycloh | 1999 |
The dexamethasone suppression test in Alzheimer's disease and major depression: relationship to dementia severity, depression, and CSF monoamines.
Topics: Aged; Alzheimer Disease; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; Hydr | 1990 |
[Current developments related to the neuroleptic malignant syndrome].
Topics: Calcium; Depressive Disorder; Fever; Homovanillic Acid; Humans; Muscle Contraction; Neuroleptic Mali | 1990 |
Neuroendocrine changes in depression.
Topics: Biogenic Amines; Depressive Disorder; Dexamethasone; Growth Hormone; Homovanillic Acid; Humans; Hydr | 1985 |
Human aggression and suicide.
Topics: Adolescent; Adult; Aggression; Animals; Depressive Disorder; Disease Models, Animal; Female; Grief; | 1986 |
Alcoholism and suicide.
Topics: Adult; Age Factors; Alcoholism; Depressive Disorder; Female; Glucose; Homovanillic Acid; Humans; Hyd | 1986 |
Overview: toward a dysregulation hypothesis of depression.
Topics: Animals; Antidepressive Agents; Arousal; Body Temperature Regulation; Circadian Rhythm; Depressive D | 1985 |
Psychiatric disorders in parkinsonism. 1. Functional illnesses and personality.
Topics: Antidepressive Agents; Clozapine; Depressive Disorder; Dopamine; Electroconvulsive Therapy; Female; | 1986 |
26 trials available for homovanillic acid and Depressive Disorder
| Article | Year |
|---|---|
Central neurochemical ultradian variability in depression.
Topics: Adult; Antidepressive Agents; Bupropion; Depressive Disorder; Female; Homovanillic Acid; Humans; Hyd | 2006 |
Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study.
Topics: Adult; Aged; Brain-Derived Neurotrophic Factor; Depressive Disorder; Electroconvulsive Therapy; Fema | 2008 |
Antidepressant effect of femoxetine and desipramine and relationship to the concentration of amine metabolites in cerebrospinal fluid. A double-blind evaluation.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder; Desipramine; Double-Blind Method; Female; G | 1982 |
Monoamine metabolites in cerebrospinal fluid of depressed patients during treatment with mianserin or amitriptyline.
Topics: Adult; Aged; Amitriptyline; Depressive Disorder; Dibenzazepines; Double-Blind Method; Female; Glycol | 1982 |
A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a norepinephrine uptake inhibitor, in endogenous depression: clinical and biochemical findings.
Topics: Adult; Aged; Clinical Trials as Topic; Depressive Disorder; Desipramine; Female; Homovanillic Acid; | 1984 |
Effects of antidepressant treatments on dopamine turnover in depressed patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antidepressive Agents; Bipolar Disorder; Brompheniramine; Clo | 1983 |
The effect of chronic alprazolam on sleep and bioamine metabolites in depression.
Topics: Adult; Alprazolam; Depressive Disorder; Double-Blind Method; Homovanillic Acid; Humans; Hydroxyindol | 1994 |
Drug-induced actions on brain neurotransmitter systems and changes in the behaviors and emotions of depressed patients.
Topics: Amitriptyline; Behavior; Bipolar Disorder; Brain Chemistry; Depressive Disorder; Double-Blind Method | 1994 |
Response to SSRI antidepressants correlates with reduction in plasma HVA: pilot study.
Topics: Adult; Aged; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Homovanillic Acid; Humans | 1993 |
Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine.
Topics: Adult; Depressive Disorder; Homovanillic Acid; Humans; Male; Monoamine Oxidase Inhibitors; Paroxetin | 1993 |
Catatonia: short-term response to lorazepam and dopaminergic metabolism.
Topics: Acute Disease; Adult; Anti-Anxiety Agents; Anxiety; Catatonia; Depressive Disorder; Dopamine; Dyskin | 1995 |
Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors.
Topics: Adult; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrati | 1997 |
Cholecystokinin in CSF from depressed patients: possible relations to severity of depression and suicidal behaviour.
Topics: Adult; Aged; Anxiety; Blood Glucose; Cholecystokinin; Depressive Disorder; Female; Homovanillic Acid | 1998 |
Bupropion slow-release response in depression: diagnosis and biochemistry.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depressive | 1998 |
Hypothalamic-pituitary-adrenal axis effects on plasma homovanillic acid in man.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Corticotropin-Releasing Hormone; Cross- | 1999 |
Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Brain; Bupropion; Cross-Over | 1999 |
Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker?
Topics: Adult; alpha-Methyltyrosine; Catecholamines; Cross-Over Studies; Depressive Disorder; Double-Blind M | 1999 |
Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents, Second-Generation; Catecholamines; | 2002 |
Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients.
Topics: Adult; Brain; Depressive Disorder; Double-Blind Method; Female; Growth Hormone; Homovanillic Acid; H | 1991 |
Effects of phosphatidylserine therapy in geriatric patients with depressive disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Arousal; beta-Endorphin; beta-Lipotropin; C | 1990 |
Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Clorgyline; Depressive Disorder; Desipramine; Female; Gly | 1985 |
Reserpine augmentation of desipramine in refractory depression: clinical and neurobiological effects.
Topics: Adult; Aged; Behavior; Blood Pressure; Body Temperature; Depressive Disorder; Desipramine; Drug Resi | 1987 |
A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients.
Topics: Adult; Aged; Anthracenes; Blood Platelets; Citalopram; Clinical Trials as Topic; Depressive Disorder | 1987 |
Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines.
Topics: Adult; Benzamides; Biogenic Monoamines; Depressive Disorder; Double-Blind Method; Female; Homovanill | 1989 |
A.E. Bennett award paper. Experimental approaches to human stress research: assessment of neurobiological mechanisms of stress in volunteers and psychiatric patients.
Topics: Adrenocorticotropic Hormone; Adult; Arousal; beta-Endorphin; Blood Glucose; Clinical Trials as Topic | 1989 |
Bupropion in depression. I. Biochemical effects and clinical response.
Topics: Adult; Bupropion; Clinical Trials as Topic; Depressive Disorder; Dopamine; Double-Blind Method; Fema | 1988 |
164 other studies available for homovanillic acid and Depressive Disorder
| Article | Year |
|---|---|
Preliminary validation of natural depression in macaques with acute treatments of the fast-acting antidepressant ketamine.
Topics: Animals; Antidepressive Agents; Conditioning, Operant; Depressive Disorder; Disease Models, Animal; | 2019 |
Evidence for reduced homovanillic acid (HVA) in the cerebrospinal fluid of patients with depression.
Topics: Depression; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Neurotransmitt | 2019 |
Low level of evidence for reduced homovanillic acid (HVA) in the cerebrospinal fluid of patients with depression compared to healthy non-psychiatric control individuals.
Topics: Depression; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Neurotransmitt | 2019 |
Positive association between the plasma levels of 5-hydroxyindoleacetic acid and the severity of depression in patients with chronic obstructive pulmonary disease.
Topics: Aged; Aged, 80 and over; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 2013 |
Cerebrospinal fluid monoamine metabolites and suicide.
Topics: Adult; Aggression; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Intenti | 2009 |
Relationship between cortisol and serotonin metabolites and transporters in alcoholism [correction of alcolholism].
Topics: Adult; Affect; Alcoholism; Carrier Proteins; Case-Control Studies; Corticotropin-Releasing Hormone; | 2002 |
Lifetime burden of mood swings and activation of brain norepinephrine turnover in patients with treatment-refractory depressive illness.
Topics: Antidepressive Agents; Brain; Depressive Disorder; Drug Resistance; Female; Homovanillic Acid; Human | 2003 |
Lower CSF homovanillic acid levels in depressed patients with a history of alcoholism.
Topics: Adult; Alcoholism; Case-Control Studies; Chi-Square Distribution; Chromatography, High Pressure Liqu | 2003 |
[Pseudopheochromocytoma in Parkinson disease and depression].
Topics: Adrenal Gland Neoplasms; Antidepressive Agents; Antiparkinson Agents; Catecholamines; Depressive Dis | 2003 |
Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment.
Topics: Adult; Aged; Biomarkers; Cyclopropanes; Depressive Disorder; Female; Homovanillic Acid; Hospitals, U | 2004 |
Both long and brief maternal separation produces persistent changes in tissue levels of brain monoamines in middle-aged female rats.
Topics: Aging; Animals; Biogenic Monoamines; Brain; Depressive Disorder; Dopamine; Down-Regulation; Female; | 2007 |
Monoamine metabolites level in CSF is related to the 5-HTT gene polymorphism in treatment-resistant depression.
Topics: Adult; Aged; Biogenic Monoamines; Brain Chemistry; Depressive Disorder; DNA Mutational Analysis; Dru | 2007 |
The relationship between CSF HVA/5-HIAA ratio and suicide intent in suicide attempters.
Topics: Adult; Biomarkers; Case-Control Studies; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindo | 2007 |
Cerebrospinal fluid monoamine metabolites and suicide.
Topics: Biomarkers; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Predictive Val | 2007 |
Dehydroepiandrosterone and monoamines in the limbic system of a genetic animal model of childhood depression.
Topics: Animals; Biogenic Monoamines; Brain Chemistry; Child; Data Interpretation, Statistical; Dehydroepian | 2008 |
Dehydroepiandrosterone in the nucleus accumbens is associated with early onset of depressive-behavior: a study in an animal model of childhood depression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age of Onset; Animals; Biogenic Monoamines; Child; Dehydroepiandrost | 2007 |
The reward system and maternal behavior in an animal model of depression: a microdialysis study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Animals, Newborn; Behavior, Animal; Body Weigh | 2008 |
HPT axis, CSF monoamine metabolites, suicide intent and depression severity in male suicide attempters.
Topics: Adult; Control Groups; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mal | 2008 |
Isocratic analysis of 3-methoxy-4-hydroxyphenyl glycol, 5-hydroxyindole-3-acetic acid and 4-hydroxy-3-methoxyphenylacetic acid in cerebrospinal fluid by high-performance liquid chromatography with amperometric detection.
Topics: Buffers; Chromatography, High Pressure Liquid; Depressive Disorder; Glycols; Homovanillic Acid; Huma | 1984 |
Monoamine metabolites in cerebrospinal fluid of depressive subgroups.
Topics: Adult; Alcoholism; Bipolar Disorder; Depressive Disorder; Female; Glycols; Homovanillic Acid; Humans | 1980 |
[Cerebrospinal HVA and 5-HIAA in patients with endogenous depression in the course of treatment].
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Bromocriptine; Depressive Disorder; Electroconvulsive | 1980 |
Correlation of individual symptoms and other clinical variables with cerebrospinal fluid amine metabolites and tryptophan in depression.
Topics: Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Phenylacetates; Tr | 1981 |
Biogenic amine disturbances in cerebrospinal fluid in parkinsonism and unipolar depression: use of the probenecid method.
Topics: Aged; Dementia; Depressive Disorder; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1981 |
Monoamine metabolites in CSF and suicidal behavior.
Topics: Adult; Age Factors; Aged; Body Height; Depressive Disorder; Female; Follow-Up Studies; Glycols; Homo | 1981 |
Cerebrospinal fluid amine metabolites, tryptophan and clinical parameters in depression. Part 1. Background variables.
Topics: Age Factors; Body Height; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1981 |
Cerebrospinal fluid amine metabolites, tryptophan and clinical parameters in depression. Part 2. Psychopathological symptoms.
Topics: Anxiety; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Phenylace | 1981 |
The influence of age, height, and body weight on cerebrospinal fluid amine metabolites and tryptophan in women.
Topics: Adult; Age Factors; Alcoholism; Body Height; Body Weight; Depressive Disorder; Female; Homovanillic | 1981 |
Neuroendocrine and neurochemical measurements in depression.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder; Dexamethasone; Glycols; Homovanillic Acid; Human | 1981 |
Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid: I. General patterns.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder; Female; Glycols; Homovanillic Acid; Humans; Hydr | 1980 |
Bromocriptine treatment of depressive disorders. Clinical and biochemical effects.
Topics: Adult; Aged; Bromocriptine; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleace | 1981 |
Serotonin and dopamine disturbances in patients with unipolar depression and Parkinsonism.
Topics: Brain; Depressive Disorder; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; M | 1981 |
Statistical power in biological psychiatry.
Topics: Depressive Disorder; Dexamethasone; Homovanillic Acid; Humans; Hydrocortisone; Hydroxyindoleacetic A | 1981 |
Gradients of monoamine metabolites and cortisol in cerebrospinal fluid of psychiatric patients and healthy controls.
Topics: Body Height; Depressive Disorder; Glycols; Homovanillic Acid; Humans; Hydrocortisone; Hydroxyindolea | 1982 |
Pre-treatment neurotransmitter metabolites and response to imipramine or amitriptyline treatment.
Topics: Amitriptyline; Depressive Disorder; Drug Evaluation; Female; Homovanillic Acid; Humans; Hydroxyindol | 1982 |
CSF monoamine metabolites during treatment with mianserin or amitryptyline.
Topics: Adult; Aged; Amitriptyline; Biogenic Amines; Depressive Disorder; Dibenzazepines; Female; Homovanill | 1982 |
Drug treatment of suicidal behaviour.
Topics: Antidepressive Agents; Brain Chemistry; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindol | 1982 |
A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. II. Biochemical findings.
Topics: Adult; Aged; Animals; Antidepressive Agents; Blood Platelets; Brompheniramine; Depressive Disorder; | 1982 |
Early morning awakening in unipolar depressives with higher levels of platelet MAO activity.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Blood Platelets; Depressive Disorder; Female; Homovanilli | 1982 |
Neurotransmitter functions in depression.
Topics: Catechol O-Methyltransferase; Depressive Disorder; gamma-Aminobutyric Acid; Homovanillic Acid; Human | 1982 |
Patterns of depression reflected in pituitary - thyroid and pituitary - adrenal endocrine changes.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Depressive Disorder; Dexamethasone; Homovanillic Acid; Hu | 1982 |
Purine and monoamine metabolites in cerebrospinal fluid: parallel purinergic and monoaminergic activation in depressive illness?
Topics: Adult; Aged; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Hypox | 1983 |
Acid metabolites and precursor amino acids of 5-hydroxytryptamine and dopamine in affective and other psychiatric disorders.
Topics: Adjustment Disorders; Adult; Aged; Amino Acids; Bipolar Disorder; Depressive Disorder; Dopamine; Fem | 1983 |
Relationship between cerebrospinal fluid amine metabolites, neuroendocrine findings and personality dimensions (Marke-Nyman scale factors) in psychiatric patients.
Topics: Alcoholism; Bipolar Disorder; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; | 1983 |
Reliability of urinary monoamine and metabolite output measurements in depressed patients.
Topics: Depressive Disorder; Dopamine; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; | 1983 |
Depression and somatosensory evoked potentials: I. Correlations between SEP and monoamine and purine metabolites in CSF.
Topics: Adult; Depressive Disorder; Evoked Potentials, Somatosensory; Female; Fingers; Glycols; Homovanillic | 1983 |
Amine metabolites and neuroendocrine responses related to depression and suicide.
Topics: Alcoholism; Depression; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; Hydro | 1983 |
The effect of dexamethasone on cerebrospinal fluid monoamine metabolites and cortisol in psychiatric patients.
Topics: Adult; Aged; Alcoholism; Bipolar Disorder; Depressive Disorder; Dexamethasone; Female; Homovanillic | 1983 |
Monoamine metabolites as predictors of antidepressant response: a critique.
Topics: Antidepressive Agents; Brain; Depressive Disorder; Dopamine beta-Hydroxylase; Homovanillic Acid; Hum | 1983 |
CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis.
Topics: Adult; Affective Disorders, Psychotic; Biogenic Amines; Bipolar Disorder; Depressive Disorder; Epine | 1983 |
Cerebrospinal fluid biochemical examinations: do they reflect clinical or biological differences?
Topics: Adult; Aged; Alcoholism; Bipolar Disorder; Calcium; Depressive Disorder; Dexamethasone; Female; Homo | 1983 |
Amine metabolites, neuroendocrine findings, and personality dimensions as correlates of suicidal behavior.
Topics: Adult; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; Hydrocortisone; Hydrox | 1983 |
Effects of electroconvulsive treatment on monoamine metabolites, growth hormone, and prolactin in plasma.
Topics: Adult; Aged; Depressive Disorder; Electroconvulsive Therapy; Female; Growth Hormone; Homovanillic Ac | 1984 |
CSF monoamine metabolites in melancholia.
Topics: Adult; Age Factors; Aged; Bipolar Disorder; Depressive Disorder; Female; Glycols; Homovanillic Acid; | 1984 |
Life at risk: markers of suicidality in depression.
Topics: Adult; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; Hydrocortisone; Hydrox | 1983 |
CSF monoamine metabolites of depressed patients during illness and after recovery.
Topics: Adult; Depressive Disorder; Female; Follow-Up Studies; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1984 |
Cerebrospinal fluid measures of neurotransmitter changes associated with pharmacological alteration of the despair response to social separation in rhesus monkeys.
Topics: alpha-Methyltyrosine; Animals; Anxiety, Separation; Behavior, Animal; Depressive Disorder; Disease M | 1984 |
Some clinical and biochemical predictors of outcome in depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Female; Homovanillic Acid | 1984 |
Neuroendocrine aspects of the relief of melancholia by induced seizures (electroconvulsive treatment).
Topics: Biogenic Amines; Brain; Catatonia; Cushing Syndrome; Depressive Disorder; Electroconvulsive Therapy; | 1984 |
Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Bipolar Disorder; Depressive Disorder; Female; Homo | 1984 |
CSF neurochemistry of women with anorexia nervosa and normal women.
Topics: Adolescent; Adult; Anorexia Nervosa; Body Weight; Calcium; Choline; Depressive Disorder; Female; gam | 1984 |
CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls.
Topics: Adolescent; Adult; Age Factors; Aged; Bipolar Disorder; Calcium; Choline; Depressive Disorder; Femal | 1984 |
Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders.
Topics: Adult; Age Factors; Bipolar Disorder; Depressive Disorder; Female; gamma-Aminobutyric Acid; Homovani | 1982 |
Imbalance of brain monoamines and clinical disorders.
Topics: Biogenic Amines; Brain; Depressive Disorder; Dopamine; Homovanillic Acid; Humans; Nervous System Dis | 1982 |
An association between low levels of 5-HIAA and HVA in cerebrospinal fluid and early mortality in a diagnostically mixed psychiatric sample.
Topics: Adult; Aged; Cause of Death; Depressive Disorder; Follow-Up Studies; Homovanillic Acid; Hospital Rec | 1993 |
The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients.
Topics: Aged; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methox | 1994 |
Depressive mania versus agitated depression: biogenic amine and hypothalamic-pituitary-adrenocortical function.
Topics: Adult; Aged; Biogenic Amines; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; | 1994 |
Are cerebrospinal fluid or urinary monoamine metabolite measures stronger correlates of suicidal behavior in depression?
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Depressive Disorder; Dopamine; Female; Homovanillic Aci | 1994 |
Effects of monoamine oxidase A inhibition on plasma biogenic amine metabolites in depressed patients.
Topics: Adult; Arousal; Benzamides; Biogenic Amines; Bipolar Disorder; Chromatography, High Pressure Liquid; | 1994 |
Biogenic amine metabolites in delusional (psychotic) depression and melancholia subtypes of major depression.
Topics: Biogenic Amines; Delusions; Depressive Disorder; Diagnosis, Differential; Dopamine; Female; Homovani | 1994 |
CSF 5-HIAA and atmospheric pressure: failure to replicate.
Topics: Atmospheric Pressure; Body Height; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacet | 1993 |
Biogenic amines in seasonal affective disorder: effects of light therapy.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1993 |
Neurochemistry and paroxetine response in major depression.
Topics: Adult; Depressive Disorder; Dose-Response Relationship, Drug; Female; Homovanillic Acid; Humans; Mal | 1995 |
The influence of total sleep deprivation on urinary excretion of catecholamine metabolites in major depression.
Topics: Adult; Aged; Catecholamines; Chromatography, Liquid; Depressive Disorder; Female; Homovanillic Acid; | 1993 |
Serum lipids in suicide attempters.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Brain; Depressive Disorder; Female; Homovanillic Acid; H | 1995 |
Cerebrospinal fluid monoamine metabolism in a case of neuroleptic malignant syndrome improved by electroconvulsive therapy.
Topics: Antidepressive Agents; Antipsychotic Agents; Depressive Disorder; Electroconvulsive Therapy; Female; | 1996 |
Attempted suicide characteristics and cerebrospinal fluid amine metabolites in depressed inpatients.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Depressive Disorder; Female; Homovanillic Acid; H | 1996 |
Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients.
Topics: Adult; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Metho | 1997 |
Plasma HVA and MHPG in psychiatric patients with renal failure and levodopa-treated Parkinson's disease.
Topics: Adult; Aged; Depressive Disorder; Female; Homovanillic Acid; Humans; Kidney Failure, Chronic; Levodo | 1996 |
Serotonergic, noradrenergic, and dopaminergic measures in suicide brains.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; Adult; Brain; Depressive Disorder; Dopamine; Fe | 1997 |
Clinical characteristics and biological parameters in temperamental clusters of suicide attempters.
Topics: Adolescent; Adult; Aged; Cluster Analysis; Depressive Disorder; Dexamethasone; Female; Homovanillic | 1997 |
Single and repeated electroconvulsive shocks activate dopaminergic and 5-hydroxytryptaminergic neurotransmission in the frontal cortex of rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Depressive Disorder; Dopamine; Electric Stimulation; Electr | 1998 |
Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders.
Topics: Adult; Brain; Brain Chemistry; Calorimetry, Indirect; Carbon Dioxide; Carrier Proteins; Catecholamin | 2000 |
Changes of cerebrospinal fluid monoamine metabolites during long-term antidepressant treatment.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Dysthymic Disorder; Female; Homovanillic Acid; Hu | 2000 |
Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syndrome: preliminary findings.
Topics: Adult; Anxiety Disorders; Blood-Brain Barrier; Cohort Studies; Depressive Disorder; Fatigue Syndrome | 1992 |
Folate deficiency, biopterin and monoamine metabolism in depression.
Topics: Adult; Aged; Biogenic Monoamines; Biopterins; Cerebrospinal Fluid; Depressive Disorder; Female; Homo | 1992 |
CSF amine metabolites in depression.
Topics: Adult; Chromatography, High Pressure Liquid; Depressive Disorder; Female; Homovanillic Acid; Humans; | 1992 |
Prediction of suicidal behavior from biologic tests.
Topics: Aged; Depressive Disorder; Dexamethasone; Epinephrine; Female; Homovanillic Acid; Humans; Hydrocorti | 1992 |
CSF 5-HIAA and atmospheric pressure.
Topics: Adult; Atmospheric Pressure; Body Height; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyind | 1992 |
The REM rhythm of depression in daytime and sleep EEG.
Topics: Circadian Rhythm; Depressive Disorder; Dexamethasone; Electroencephalography; Female; Homovanillic A | 1992 |
Reduction of CSF monoamine metabolites in poststroke depression: a preliminary report.
Topics: Adult; Aged; Cerebral Infarction; Depressive Disorder; Dominance, Cerebral; Female; Homovanillic Aci | 1992 |
Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome.
Topics: Adult; Bupropion; Depressive Disorder; Fatigue Syndrome, Chronic; Female; Fluoxetine; Follow-Up Stud | 1992 |
Neuroleptic malignant syndrome: a study of CSF monoamine metabolism.
Topics: Adult; Biogenic Monoamines; Bipolar Disorder; Depressive Disorder; Female; Homovanillic Acid; Humans | 1990 |
CSF 5-HIAA and HVA concentrations in elderly depressed patients who attempted suicide.
Topics: Age Factors; Aged; Analysis of Variance; Depressive Disorder; Female; Homovanillic Acid; Hospitaliza | 1990 |
Intercorrelations among monoamine metabolite concentrations in human lumbar CSF are not due to a shared acid transport system.
Topics: Acid-Base Equilibrium; Administration, Oral; Blood-Brain Barrier; Depressive Disorder; Dose-Response | 1990 |
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPS, HIAA, and HVA levels of cerebrospinal fluid.
Topics: Carboxy-Lyases; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Le | 1990 |
Effects of clomipramine treatment on cerebrospinal fluid monoamine metabolites and platelet 3H-imipramine binding and serotonin uptake and concentration in major depressive disorder.
Topics: Adult; Blood Platelets; Carrier Proteins; Clomipramine; Depressive Disorder; Female; Homovanillic Ac | 1991 |
Concentrations of cerebrospinal fluid monoamine metabolites in suicides.
Topics: 3,4-Dihydroxyphenylacetic Acid; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1991 |
CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression.
Topics: Aged; Alzheimer Disease; Depressive Disorder; Diagnosis, Differential; Female; Homovanillic Acid; Hu | 1991 |
Lateral ventricle-brain ratio and balance between CSF HVA and 5-HIAA in schizophrenia.
Topics: Adult; Age Factors; Bipolar Disorder; Body Height; Body Weight; Brain; Brain Chemistry; Cerebral Ven | 1991 |
Reduced cerebrospinal fluid dynorphin A1-8 in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain; Depressive Disorder; Dynorphins; Female; Galanin; Homovanillic Acid; | 1991 |
CSF GABA in depressed patients and normal controls.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Female; gamma-Aminobutyric Acid; Homovanillic Acid; Hu | 1991 |
Memory effects of clomipramine treatment: relationship to CSF monoamine metabolites and drug concentrations in plasma.
Topics: Adult; Aged; Attention; Brain; Clomipramine; Depressive Disorder; Female; Homovanillic Acid; Humans; | 1991 |
Measures of serotonin metabolism in anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1991 |
Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis.
Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Chromatography, High Pressure Liquid; Depressive | 1991 |
MMPI measures of impulsivity and depression correlate with CSF 5-HIAA and HVA in depression but not schizophrenia.
Topics: Adult; Depressive Disorder; Homovanillic Acid; Humans; Impulsive Behavior; Male; Middle Aged; MMPI; | 1991 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables.
Topics: Adult; Age Factors; Alcohol Drinking; Alcoholism; Anxiety Disorders; Depressive Disorder; Divorce; D | 1991 |
Neuropsychological profile linked to low dopamine: in Alzheimer's disease, major depression, and Parkinson's disease.
Topics: Aged; Alzheimer Disease; Attention; Depressive Disorder; Dopamine; Homovanillic Acid; Humans; Male; | 1990 |
Sensory gating deficits in psychiatric inpatients: relation to catecholamine metabolites in different diagnostic groups.
Topics: Adult; Arousal; Attention; Bipolar Disorder; Brain; Catecholamines; Depressive Disorder; Evoked Pote | 1990 |
Hallucinations in patients with major depression. Interactions between CSF monoaminergic and endorphinergic indices.
Topics: Adult; Age Factors; Bipolar Disorder; Depressive Disorder; Endorphins; Female; Hallucinations; Homov | 1985 |
Human aggression and the role of central serotonin.
Topics: Aggression; Brain; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Interpe | 1985 |
Higher CSF levels of HVA and 5-HIAA in delusional compared to nondelusional depression.
Topics: Adult; Aged; Delusions; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1985 |
Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Bipolar Disorder; Depressive Disorder; Dopamine; Female | 1985 |
Effects of ECT on sleep and CSF biogenic amines in affective illness.
Topics: Adult; Biogenic Amines; Bipolar Disorder; Depressive Disorder; Electroconvulsive Therapy; Homovanill | 1985 |
Biological markers in depression. Monoamine metabolites in urine of depressed patients and normal subjects.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Female; Glycols; Homovanillic Acid; Humans; Hydro | 1985 |
Clinical and biochemical features of depression in Parkinson's disease.
Topics: Aged; Depressive Disorder; Dexamethasone; Growth Hormone; Homovanillic Acid; Humans; Hydroxyindoleac | 1986 |
Tricyclic antidepressant washout effects on cerebrospinal fluid and urinary monoamine and metabolites.
Topics: Amines; Antidepressive Agents, Tricyclic; Depressive Disorder; Epinephrine; Homovanillic Acid; Human | 1986 |
Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic, and healthy control subjects.
Topics: Bipolar Disorder; Depressive Disorder; Female; Glycols; Homovanillic Acid; Hospitalization; Humans; | 1986 |
Consistent evidence for a biological subtype of depression characterized by low CSF monoamine levels.
Topics: Depressive Disorder; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Methoxyhydroxyphe | 1986 |
Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF.
Topics: Adolescent; Adult; Aged; Animals; Brain; Brain Chemistry; Depressive Disorder; Dogs; Dopamine; Femal | 1986 |
Reduced CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindoleacetic acid ratios in depressed patients: relationship to suicidal behavior and dexamethasone nonsuppression.
Topics: Adult; Aged; Aged, 80 and over; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Human | 1986 |
Discrimination of idiopathic pain syndromes from neurogenic pain syndromes and healthy volunteers by means of clinical rating, personality traits, monoamine metabolites in CSF, serum cortisol, platelet MAO and urinary melatonin.
Topics: Adult; Chronic Disease; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydrocortisone; Hydr | 1986 |
Depression and Parkinson's disease.
Topics: Depressive Disorder; Dexamethasone; Growth Hormone; Homovanillic Acid; Humans; Hydrocortisone; Hydro | 1987 |
5-Hydroxytryptophan-induced cortisol response and CSF 5-HIAA in depressed patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; Adult; Brain; Depressive Disorder; Female; Homo | 1987 |
Cerebrospinal fluid correlates of suicide attempts and aggression.
Topics: Aggression; Animals; Bipolar Disorder; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindole | 1986 |
Aminergic studies and cerebrospinal fluid cations in suicide.
Topics: Adult; Aged; Calcium; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Ac | 1986 |
Studies of amine metabolites in depressed patients. Relationship to suicidal behavior.
Topics: Bipolar Disorder; Brain; Depressive Disorder; Epinephrine; Homovanillic Acid; Humans; Hydrocortisone | 1986 |
Cerebrospinal fluid studies in suicide. An overview.
Topics: Aggression; Brain; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Methoxy | 1986 |
Platelet tritiated imipramine binding and serotonin uptake in depressed patients and controls. Relationship to plasma cortisol levels before and after dexamethasone administration.
Topics: Adult; Blood Platelets; Carrier Proteins; Depressive Disorder; Dexamethasone; Female; Homovanillic A | 1987 |
5-HIAA and HVA in CSF in patients with idiopathic pain disorders.
Topics: Adult; Age Factors; Aged; Body Weight; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydro | 1987 |
Diurnal rhythms of plasma cortisol, beta-endorphin and prolactin, and cerebrospinal fluid amine metabolite levels before suicide. Case report.
Topics: beta-Endorphin; Catecholamines; Circadian Rhythm; Depressive Disorder; Endorphins; Homovanillic Acid | 1986 |
CSF amine metabolites and depression.
Topics: Adult; Aged; Depressive Disorder; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male | 1987 |
Biogenic amine and metabolite levels in depressed patients with high versus normal hypothalamic-pituitary-adrenocortical activity.
Topics: Biogenic Amines; Depressive Disorder; Dexamethasone; Epinephrine; Homovanillic Acid; Humans; Hydroco | 1987 |
CSF-amine metabolites in depression, dementia and in controls.
Topics: Biogenic Amines; Body Height; Dementia; Depressive Disorder; Homovanillic Acid; Humans; Hydrocephalu | 1987 |
TRH stimulation test and depression.
Topics: Adult; Aged; Depressive Disorder; Dexamethasone; Homovanillic Acid; Humans; Hydrocortisone; Hydroxyi | 1987 |
The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5-hydroxyindoleacetic acid ratio.
Topics: Alzheimer Disease; Antidepressive Agents; Cerebrospinal Fluid; Depressive Disorder; Drug Evaluation; | 1987 |
Monoamine neurotransmitter interactions and the prediction of antidepressant response.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Female; Glycols; Homovanillic Acid; Humans; Hydro | 1987 |
CSF monoamine metabolites in chronic pain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Back Pain; Biogenic Amines; Chronic Disease; Depressive | 1987 |
Neurochemical variables in delusional depression.
Topics: Adult; Blood Platelets; Cyclic AMP; Delusions; Depressive Disorder; Dopamine; Dopamine beta-Hydroxyl | 1988 |
Pathological gambling. A psychobiological study.
Topics: Adult; Brain; Corticotropin-Releasing Hormone; Depressive Disorder; Disruptive, Impulse Control, and | 1988 |
Cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls.
Topics: Biogenic Amines; Circadian Rhythm; Depressive Disorder; Epinephrine; Female; Homovanillic Acid; Huma | 1988 |
Seasonal changes of CSF monoamine metabolites in psychiatric patients: what is the source?
Topics: Bipolar Disorder; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mental D | 1988 |
CSF biochemical correlates of mixed affective states.
Topics: Adult; Bipolar Disorder; Calcium; Depressive Disorder; Electrolytes; Female; Homovanillic Acid; Huma | 1988 |
Corrections to a 1980 article on CSF monoamine metabolites.
Topics: 3,4-Dihydroxyphenylacetic Acid; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1989 |
Relationships between clinical symptoms and monoamine metabolite concentrations in biochemically defined subgroups of depressed patients.
Topics: Depressive Disorder; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Methoxyhydroxyphe | 1988 |
Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters. A follow-up study.
Topics: Adult; Alcoholism; Blood Glucose; Criminal Psychology; Depressive Disorder; Disruptive, Impulse Cont | 1989 |
Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow-up study.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Dopamine; Female; Follow-Up Studies; Homovanillic Acid | 1989 |
Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid.
Topics: Adult; Aged; Depressive Disorder; Female; Fluoxetine; Glycols; Homovanillic Acid; Humans; Hydroxyind | 1989 |
Cerebrospinal fluid magnesium and calcium related to amine metabolites, diagnosis, and suicide attempts.
Topics: Adjustment Disorders; Adult; Aged; Calcium; Depressive Disorder; Dexamethasone; Female; Homovanillic | 1985 |
Effects of amitriptyline and imipramine on brain amine neurotransmitter metabolites in cerebrospinal fluid.
Topics: Adult; Amitriptyline; Bipolar Disorder; Depressive Disorder; Dopamine; Double-Blind Method; Female; | 1985 |
Acute and subacute effects of ECT on plasma HVA, MHPG, and prolactin.
Topics: Adult; Depressive Disorder; Electroconvulsive Therapy; Female; Glycols; Homovanillic Acid; Humans; M | 1989 |
Specificity of plasma HVA response to dexamethasone in psychotic depression.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Depressive Disorder; Dexamethasone; Female; | 1989 |
Biochemical aspects of dysphoria: case study for hypothesis generation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Affective Disorders, Psychotic; Aged; Bipolar Disorder; Brain; Depre | 1987 |
[Features of the functioning of the catecholamine and adrenocortical systems of patients with depression and different degrees of emotional tension].
Topics: 11-Hydroxycorticosteroids; Adrenal Cortex; Catecholamines; Depressive Disorder; Dexamethasone; Dihyd | 1986 |
The diurnal variation in plasma homovanillic acid level persists but the variation in 3-methoxy-4-hydroxyphenylglycol level is abolished under constant conditions.
Topics: Adult; Circadian Rhythm; Depressive Disorder; Diet; Dopamine; Female; Glycols; Homovanillic Acid; Hu | 1988 |
High correlations of norepinephrine, dopamine, and epinephrine and their major metabolite excretion rates.
Topics: Adult; Alcoholism; Circadian Rhythm; Depressive Disorder; Dopamine; Epinephrine; Female; Homovanilli | 1988 |
Characteristics of patients with the highest plasma catecholamine metabolite levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Depressive Disorder; Feeding and Eating Disorders; Femal | 1988 |
The effects of dexamethasone on plasma homovanillic acid and 3-methoxy-4-hydroxyphenylglycol. Evidence for abnormal corticosteroid-catecholamine interactions in major depression.
Topics: Adult; Aged; Bipolar Disorder; Circadian Rhythm; Depressive Disorder; Dexamethasone; Diagnosis, Diff | 1987 |
Plasma catecholamine metabolites in subtypes of major depression.
Topics: Adult; Aged; Aged, 80 and over; Depressive Disorder; Dexamethasone; Female; Glycols; Homovanillic Ac | 1987 |
Urinary monoamines and monoamine metabolites in subtypes of unipolar depressive disorder and normal controls.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Catecholamines; Depressive Disorder; Dopamine; Female; | 1986 |
CSF cortisol in affective illness.
Topics: Circadian Rhythm; Depressive Disorder; Dexamethasone; Homovanillic Acid; Humans; Hydrocortisone; Met | 1985 |
Elevated plasma homovanillic acid in depressed females with melancholia and psychosis.
Topics: Adult; Depressive Disorder; Female; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Mid | 1985 |
Dopaminergic effects of carbamazepine. Relationship to clinical response in affective illness.
Topics: Adult; Animals; Carbamazepine; Depressive Disorder; Dopamine; Female; Homovanillic Acid; Humans; Mal | 1986 |
Dexamethasone suppression test and the levels of serum growth hormone, plasma vasopressin and plasma homovanillic acid in depressed in- and outpatients.
Topics: Adolescent; Adult; Aged; Arginine Vasopressin; Bipolar Disorder; Depressive Disorder; Dexamethasone; | 1985 |